A fixed-dose combination of ledipasvir and sofosbuvir ± ribavirin for treatment of hepatitis C infection: a systematic review and meta-analysis
| Autor: | Sumit Kunwar, Ashok Raj Devkota, Prabhat Adhikari, Dipesh K. C. Ghimire |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Hepatitis
Ledipasvir medicine.medical_specialty Sofosbuvir business.industry Ribavirin Fixed-dose combination Hepatitis C medicine.disease Virology Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry Internal medicine medicine 030211 gastroenterology & hepatology Pharmacology (medical) 030212 general & internal medicine business Adverse effect Viral load medicine.drug |
| Zdroj: | Drugs & Therapy Perspectives. 33:348-360 |
| ISSN: | 1179-1977 1172-0360 |
| DOI: | 10.1007/s40267-017-0401-2 |
| Popis: | Novel antivirals have shown promising results in the treatment of hepatitis C. Our objective was to perform a meta-analysis of the efficacy and safety of a fixed-dose combination (FDC) of ledipasvir + sofosbuvir and compare outcomes with the addition of ribavirin (RBV) to treatment with the FDC. We searched PubMed, EMBASE, and Cochrane CENTRAL from inception through to 9 February 2017. We used a random effects model to calculate untransformed proportions (PRs) and pooled odds ratios (ORs) with 95% confidence intervals (CIs) to compare outcome measures [sustained virologic response at 12 weeks after treatment completion (SVR12); any, serious, and individual adverse events] between groups receiving the FDC ± RBV. We performed the systematic review according to PRISMA guidelines. A total of 21 studies with 3826 patients were included in the meta-analysis. Ledipasvir/sofosbuvir was effective in achieving SVR12 after 8 weeks of therapy in genotype (GT) 1 treatment-naive patients without cirrhosis (PR 0.941; 95% CI 0.910–0.971; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink